Critical Contrast: Mangoceuticals (MGRX) vs. Its Competitors
by Kim Johansen · The Markets DailyMangoceuticals (NASDAQ:MGRX – Get Free Report) is one of 19 public companies in the “Miscellaneous health & allied services, not elsewhere classified” industry, but how does it compare to its rivals? We will compare Mangoceuticals to similar companies based on the strength of its analyst recommendations, earnings, institutional ownership, valuation, risk, dividends and profitability.
Valuation & Earnings
This table compares Mangoceuticals and its rivals top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Mangoceuticals | $866,792.00 | -$9.21 million | -0.37 |
| Mangoceuticals Competitors | $2.39 billion | $82.32 million | 15.34 |
Mangoceuticals’ rivals have higher revenue and earnings than Mangoceuticals. Mangoceuticals is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.
Institutional & Insider Ownership
56.7% of Mangoceuticals shares are held by institutional investors. Comparatively, 61.8% of shares of all “Miscellaneous health & allied services, not elsewhere classified” companies are held by institutional investors. 39.3% of Mangoceuticals shares are held by insiders. Comparatively, 27.3% of shares of all “Miscellaneous health & allied services, not elsewhere classified” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Risk & Volatility
Mangoceuticals has a beta of 1.76, suggesting that its share price is 76% more volatile than the S&P 500. Comparatively, Mangoceuticals’ rivals have a beta of 3.97, suggesting that their average share price is 297% more volatile than the S&P 500.
Profitability
This table compares Mangoceuticals and its rivals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Mangoceuticals | -1,053.93% | -243.34% | -200.73% |
| Mangoceuticals Competitors | -816.62% | -48.14% | -36.60% |
Analyst Ratings
This is a summary of recent ratings for Mangoceuticals and its rivals, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Mangoceuticals | 0 | 0 | 0 | 0 | N/A |
| Mangoceuticals Competitors | 36 | 289 | 416 | 148 | 2.76 |
As a group, “Miscellaneous health & allied services, not elsewhere classified” companies have a potential upside of 51.50%. Given Mangoceuticals’ rivals higher probable upside, analysts plainly believe Mangoceuticals has less favorable growth aspects than its rivals.
Summary
Mangoceuticals rivals beat Mangoceuticals on 9 of the 10 factors compared.
About Mangoceuticals
Mangoceuticals, Inc. develops, markets, and sells various men's wellness products and services through a telemedicine platform in the United States. It offers erectile dysfunction (ED) products under the Mango brand and hair loss products under the Grow brand name. The company markets and sells these branded ED and hair loss products online through its website at MangoRx.com. Mangoceuticals, Inc. has a marketing agreement with Marius Pharmaceuticals, LLC to market and sell KYZATREX, an oral testosterone replacement therapy product under the PRIME program. The company was incorporated in 2021 and is headquartered in Dallas, Texas. Mangoceuticals, Inc. is a subsidiary of Cohen Enterprises, Inc.